{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for telotristat root_names_stdName in Standardized Name (approximate match)
Status:
Designated
Source:
FDA ORPHAN DRUG:568816
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:792220
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:618517
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Designated
Source:
EU-Orphan Drug:EU/3/14/1239
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:615317
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Designated
Source:
EU-Orphan Drug:EU/3/16/1654
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:485815
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:865621
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:622417
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
APREMILAST, (±)- is a mixture of isomers, one of them is therapeutic active S form (apremilast), an inhibitor of phosphodiesterase 4. This active form is sold under the brand name OTEZLA for the treatment of adult patients with active psoriatic arthritis.
Status:
Designated
Source:
FDA ORPHAN DRUG:550316
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
APC-3316 is a vinyl sulfone cystein protease inhibitor. It is a potent, irreversible cysteine protease inhibitor and a potent and selective CCR4 antagonist. Its therapeutic targets are cruzain, a cysteine protease of the protozoan parasite Trypanosoma cruzi, and cathepsins B and L, which are associated with cancer progression. It was discontinued after preclinical trials in Chagas disease in USA.
